

Product Showcases

There are 18 Product Showcases supported by pharmaceutical companies exhibiting at the meeting. The 60-minute promotional programs are an extension of the Exhibit Hall. CME credit is not provided. Seating is limited to 200 on a first-come, first-serve basis. Boxed lunches or snacks are provided.

Product Showcases are covered by the Physician Payment Sunshine Act and physicians attending will be required to provide their identifying information for public reports.

Locations:

Product Showcase 1 (Booth 3448) & Product Showcase 2 (Booth 3414) Exhibit Halls G-J, First Floor New Orleans Ernest N. Morial Convention Center

Saturday, May 21, 2022

Noon - 1:00 pm

Product Showcase #1 (Booth 3448)

Supported by Otsuka America Pharmaceutical Inc. and Lundbeck

When would you choose an LAI as a maintenance monotherapy treatment for your appropriate adult patients living with Bipolar I Disorder?

Presenters:

Greg Mattingly, MD Erin Crown, PA

1:00 - 2:00 pm

Product Showcase #2 (Booth 3414)

Supported by AbbVie

The Management of Bipolar I Depression

Presenter:

Vladimir Maletic, MD, MS

Clinical Professor of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, Columbia, South Carolina

2:00 - 3:00 pm

Product Showcase #1 (Booth 3448)

Supported by Otsuka America Pharmaceutical, Inc. and Lundbeck

The Efficacy and Safety Profile of an Adjunctive Therapy for Adult Patients with Major Depressive Disorder (MDD)

Presenter:

Rakesh Jain, MD, MPH

Saturday, May 21, 2022 (continued)

3:00 - 4:00 pm

Product Showcase #2 (Booth 3414)

Supported by TEVA

How the Social Determinants of Mental Health Relate to Neuropsychiatric Disorders - What Can We Do About Them in Clinical Practice?

Presenters:

Michael T. Compton, MD, MPH, DFAPA Cynthia E. Armand, MD Craig Chepke, MD, FAPA

Sunday, May 22, 2022

11:00 am - Noon

Product Showcase #1 (Booth 3448)

Supported by Janssen Pharmaceuticals, Inc.

Coordination of Care Between Referring Psychiatrist and Treatment Center Provider

Presenters:

Rakesh Jain, MD, MPH

Jamie Winderbaum Fernandez, MD, MSc, DFAPA

Noon - 1:00 pm

Product Showcase #2 (Booth 3414)

Supported by Sage Therapeutics, Inc. & Biogen Inc.

Challenges and Recent Advances in Understanding the Pathophysiology of Depression

Presenters:

Napoleon Higgins, Jr. MD

Chair, Bay Pointe Behavioral Health

Vladimir Maletic, MD, MS

University of South Carolina

Jamie W. Fernandez, MD, DFAPA

University of South Florida, Interventional Psychiatry of Tampa Bay

1:00 - 2:00 pm

Product Showcase #1 (Booth 3448)

Supported by Sunovion Pharmaceuticals Inc.

Is D₂ Receptor Blockade the Best TAARget for Treating Schizophrenia? Exploring A Novel Mechanism Presenters:

Craig Chepke, MD, FAPA

Jonathan Meyer, MD

Sunday, May 22, 2022 (continued)

2:00 - 3:00 pm

Product Showcase #2 (Booth 3414)

Supported by Alkermes

Learn More: An Oral Treatment Option for Adults with Schizophrenia or Bipolar I Disorder

Presenter:

Jelena Kunovac, MD, MS

Chief Scientific Officer, The IMA Group, Tarrytown, NY; Adjunct Assistant Professor, University of Nevada, Las Vegas, NV

3:00 - 4:00 pm

Product Showcase #1 (Booth 3448)

Supported by Intra-Cellular Therapies, Inc.

Clinical Evidence Supporting the Use of a New Treatment Option for Adults with Bipolar Depression:

Bipolar I or II

Presenter:

Rakesh Jain, MD, MPH

Monday, May 23, 2022

11:00 am - Noon

Product Showcase #1 (Booth 3448)

Supported by Boehringer-Ingelheim Pharmaceuticals, Inc.

Negative and Cognitive Symptom Domains in Schizophrenia

Presenters:

John M. Kane, MD

Christoph Correll, MD

Noon - 1:00 pm

Product Showcase #2 (Booth 3414)

Supported by Otsuka America Pharmaceutical, Inc.

The Evolving Role of Digital Tools and Utilization of a Treatment Option in Team-Based Psychiatric Care

Presenters:

John M. Kane, MD

Dawn I. Velligan, PhD

Craig Chepke, MD, FAPA

1:00 - 2:00 pm

Product Showcase #1 (Booth 3448)

Supported by Eisai Inc.

Insomnia Management: Real Patient Stories and Clinical Considerations

Speaker:

Greg Mattingly, MD

Associate Clinical Professor, Washington University in St. Louis; President, Midwest Research Group; Board of Directors, APSARD; Editorial Board, Journal of Attention Disorders

Monday, May 23, 2022 (continued)

2:00 - 3:00 pm

Product Showcase #2 (Booth 3414)

Supported by TEVA

Long-Acting Injectables in Schizophrenia: Dispelling Myths, Unlocking Clinical Value

Presenters:

John Kane, MD

Leslie Citrome, MD, MPH

Christoph Correll, MD

Jose Rubio, MD

3:00 - 4:00 pm

Product Showcase #1 (Booth 3448)

Supported by Supernus Pharmaceuticals, Inc.

A Nonstimulant Treatment Option for ADHD

Presenters:

Andrew J. Cutler, MD

Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University, Syracuse, NY; Chief Medical Officer, Neuroscience Education Institute, Lakewood Ranch, FL

Theresa R. Cerulli, MD

Medical Director, Cerulli and Associates, North Andover, MA; Lecturer/Clinical Supervisor, Beth Israel Deaconess Medical Center, Boston, MA

Tuesday, May 24, 2022

11:00 am - Noon

Product Showcase #1 (Booth 3448)

Supported by Axsome Therapeutics

Beyond the Monoamine Hypothesis: A Glutamatergic Approach to Treating Major Depressive Disorder Presenters:

Gus Alva, MD, DFAPA

Medical Director, ATP Clinical Research Costa Mesa, CA; Assistant Professor, University of California, Riverside Department of Neuroscience; Medical Director, Center for Senior Brain Health, Hoag Hospital, Newport Beach, CA

Greg Mattingly, MD

Associate Clinical Professor, Washington University in St. Louis, President, Midwest Research Group; Board of Directors, APSARD; Editorial Board, Journal of Attention Disorders, Washington University School of Medicine

Noon - 1:00 pm

Product Showcase #2 (Booth 3414)

Supported by Ironshore Pharmaceuticals Inc.

Paradigm Shift: A New Appreciation for Methylphenidate in Adults With ADHD

Presenters:

Greg Mattingly, MD

Birgit Amann, MD

Tuesday, May 24, 2022 (continued)

1:00 - 2:00 pm

Product Showcase #1 (Booth 3448) Supported by Idorsia Pharmaceuticals, US Inc.

Advances in the Treatment of Insomnia

Presenter:

Sachin Mehta, MD

Medical Director, Springfield Psychological, Blue Bell, PA

2:00 - 3:00 pm

Product Showcase #2 (Booth 3414)

Supported by Janssen Pharmaceuticals, Inc.

Introducing a Long-Acting Injectable (LAI) With a Longer Dosing Interval for Adult Patients With Schizophrenia

Presenter:

Rebecca Roma, MD